Scrip    Clinica    RAJ    Scrip Clinical Research    AnimalPharm   
Email ID
Password
Forgotten your password?
Sign me in automatically next time
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Cancer
|
Cardiovascular
|
Infection
|
Metabolic
|
Musculoskeletal
|
CNS
|
Respiratory
|
Gastrointestinal
|
Other
|
Therapy Sector
EVENTS
01 January 1970
London, UK
01 January 1970
San Diego, US
01 January 1970
Providence, Rhode Island, and San Francisco, California
JOB OF THE WEEK Promote your vacancy here
Ono takes further stride into oncology with Onyx deal
09 September 2010
Ono Pharmaceutical has signed its second oncology in-licensing deal in a week, this time with Onyx Pharmaceuticals for Japanese rights to two proteasome inhibitors. The agreement, Onyx's first for the two projects, gives Ono exclusive rights to develop and commercialise carfilzomib and ONX 0912 for all cancer indications in Japan. The mid-sized firm will pay ¥5.0 billion ($59.7 million) upfront at closing, plus development and sales-based payments of up to around ¥24.0 billion. Onyx will ...
 
Ono takes further stride into oncology with Onyx deal
09 September 2010
Ono Pharmaceutical has signed its second oncology in-licensing deal in a week, this time with Onyx Pharmaceuticals for Japanese rights to two proteasome inhibitors. The agreement, Onyx's first for the two projects, gives Ono exclusive rights to develop and commercialise carfilzomib and ONX 0912 ...
Lifting of Avastin conditions sets stage for wider colorectal use in Japan
09 September 2010
The conditional approval restrictions applied in Japan to Chugai/Roche's Avastin (bevacizumab) in colorectal cancer have been lifted, clearing the way for wider uptake of the anti-VEGF antibody. The country's ministry of health, labour and welfare had required an all-patient postmarketing ...
 
EU approves Merck/Cardiome's Brinavess for atrial fibrillation cardioversion
07 September 2010
The EMA has approved Merck/Cardiome's Brinavess (vernakalant) for the rapid conversion of recent onset atrial fibrillation (AF) to sinus rhythm in adults. The move comes only two months after Brinavess was given the nod by the CHMP (scripintelligence.com, 29 June 2010). The mixed sodium and ...
NEJM editorial pans Abbott's obesity drug Merida
03 September 2010
An editorial in New England Journal Medicine – penned to coincide with the publication of detailed SCOUT data on the cardiovascular safety of Abbott's fat-fighting pill Meridia (sibutramine) – has come down critically on the drug, piling yet more pressure on its maker. "Given that sibutramine has ...
 
Forest Labs' antibiotic ceftaroline gets unanimous support of FDA advisory panel
08 September 2010
Forest Labs got unanimous support from the US FDA anti-infective drugs advisory committee for its injectable antibiotic ceftaroline fosamil, with panellists agreeing that it should be approved for two indications: community acquired bacterial pneumonia and (CABP) and complicated skin and skin ...
First NDM-1 "superbug" case reported in Japan
07 September 2010
Japan has publicly disclosed the first reported case of infection with a strain of bacteria carrying the NDM-1 "superbug" gene. Dokkyo Medical University Hospital in Tochigi prefecture said that a male patient with an Escherichia coli infection was hospitalised in May last year, following a trip to ...
 
Genzyme snubs offer from Sanofi-Aventis
31 August 2010
After months of speculation Sanofi-Aventis, the French pharma major, at the weekend unveiled an all-cash $69.00 a share bid for Genzyme, which values the US biotech at about $18.5 billion. Not surprisingly, the Genzyme board unanimously rejected the offer claiming it to be "an opportunistic ...
Ipsen to acquire rights to Santhera's fipamezole
03 September 2010
In a bid to beef up its research pipeline Ipsen, the French speciality pharma company, is paying Santhera Pharmaceuticals €13 million up front for the rights to its adrenergic alpha-2 receptor antagonist fipamezole outside North America and Japan. Fipamezole is a first-in-class compound in ...
 
Studies find contradictory effects of bisphosphonates in oesophageal cancer
07 September 2010
Two studies into whether bisphosphonates are associated with oesophageal cancer have yielded contradictory conclusions. One published in the BMJ on 3 September argues that the osteoporosis drugs are associated with an increased risk of the cancer, whereas another in JAMA on 11 August found they ...
FDA panels vote against Jazz bid to sell sodium oxybate for fibromyalgia
23 August 2010
A joint meeting on 20 August of two US FDA advisory committees put major roadblocks in the way of Jazz Pharmaceuticals' new drug application (NDA) to sell sodium oxybate as a treatment for fibromyalgia. The panel of outside experts on arthritis products and drug safety and risk management, who were ...
 
EU approves Merck & Co's Sycrest for bipolar disorder
07 September 2010
The EMA has approved Merck & Co's Sycrest (asenapine) for the treatment of manic episodes in bipolar 1 disorder in adults. The atypical antipsychotic was approved for manic episodes associated with bipolar 1 disorder, and for schizophrenia, in the US last year, where it is marketed as Saphris ( ...
EMA investigates link between GSK's Pandemrix and narcolepsy
01 September 2010
The EMA has initiated a review of GlaxoSmithKline's H1N1 vaccine Pandemrix, having noted a possible link with narcolepsy. The vaccine, which was approved for use as a prophylactic vaccine in the EU in September 2009, has already been used in over 30 million Europeans. The regulators are now ...
 
Ono takes further stride into oncology with Onyx deal
09 September 2010
Ono Pharmaceutical has signed its second oncology in-licensing deal in a week, this time with Onyx Pharmaceuticals for Japanese rights to two proteasome inhibitors. The agreement, Onyx's first for the two projects, gives Ono exclusive rights to develop and commercialise carfilzomib and ONX 0912 ...
Forest Labs' antibiotic ceftaroline gets unanimous support of FDA advisory panel
08 September 2010
Forest Labs got unanimous support from the US FDA anti-infective drugs advisory committee for its injectable antibiotic ceftaroline fosamil, with panellists agreeing that it should be approved for two indications: community acquired bacterial pneumonia and (CABP) and complicated skin and skin ...
 
CJ gains access to RaQualia's acid pump antagonists
07 September 2010
RaQualia Pharma, a Japanese venture spun out from Pfizer research, has reached a licensing deal for two of its pipeline projects with a leading South Korean pharma firm. The agreement gives CJ CheilJedang exclusive rights in its home market and in China to two acid pump antagonist clinical ...
Roche to appeal against preliminary NICE no for Herceptin for metastatic gastric cancer
07 July 2010
Roche says it will appeal against preliminary draft guidance from the National Institute for health and Clinical Excellence (NICE) in England and Wales that declines to recommend Roche's HER2-targeted Herceptin (trastuzumab) for treating metastatic gastric cancer patients on the NHS. NICE says it ...
 
Studies find contradictory effects of bisphosphonates in oesophageal cancer
07 September 2010
Two studies into whether bisphosphonates are associated with oesophageal cancer have yielded contradictory conclusions. One published in the BMJ on 3 September argues that the osteoporosis drugs are associated with an increased risk of the cancer, whereas another in JAMA on 11 August found they ...
Glenmark unveils details of its TRPA1 antagonist
31 August 2010
Glenmark Pharmaceuticals is developing a TRPA1 receptor antagonist for pain and respiratory disorders. The Indian company joins at least four other firms including Hydra Biosciences, Abbott and Janssen that are known to be working in the same area. Glenmark said that its compound, GRC 17536, had ...
 
EXPERT VIEW
The lure of orphan products
06 September 2010
Peter Charlish
The global market for orphan drugs was worth almost $85 billion in 2009. Furthermore, the market is ...

2010 Scrip 100 - Mixed fortunes on the R&D front
23 August 2010

Continued problems with anti-obesity drugs, more measures designed to improve R&D efficiency, and ...

Liver cancer becomes more preventable and treatable
12 August 2010

New drugs to treat viral hepatitis infection, coupled with renewed interest from companies in ...

Rare diseases in the Middle East: prospects for CROs
28 July 2010

The treatment of rare diseases in Europe has been significantly enhanced by the EU's Orphan Drug ...

Private investment round-up: July 2010 - highest monthly investments secured so far this year
18 August 2010
A Scrip analysis has identified 21 companies that raised private investment in July, one up on the ...

Calling German and Spanish Physicists: the EMA Needs You
13 July 2010
Maureen Kenny
German or Spanish physicists hoping for a career change involving a move to London at the end of ...

GW high on pipeline of cannabis extracts
23 August 2010
Katie McQue
GW Pharma has enjoyed recent success with its cannabinoid extract product Sativex (nabiximols), ...

© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Terms & Conditions
Privacy Policy
Sitemap
About Us
Advertise
Subscribe
Scrip
Clinica
RAJ
Scrip Clinical Research
Animal Pharm